Literature DB >> 12206515

Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.

Monica M Reinholz1, Stephen J Iturria, James N Ingle, Patrick C Roche.   

Abstract

Several cytokines including members of the transforming growth factor-beta (TGF-beta) and tumor necrosis factor (TNF) families have been implicated in the homing mechanism of breast cancer metastasis. We hypothesize that primary breast tumor tissues differentially express modulators of bone cell function and that this expression pattern contributes to their aggressive and metastatic potential and to their capacity to establish and grow in bone. We, therefore, examined the gene expression pattern of the TGF-beta family members (inhibin/activin betaA subunit (activin betaA), inhibin alpha subunit, and bone morphogenetic protein-2 (BMP-2)), the TNF family members (receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG)), and osteopontin (OPN) in normal, non-invasive, invasive, and metastatic human breast cancer specimens. The mRNA transcript levels of these genes were quantified by reverse transcription (RT) and fluorescent-based kinetic PCR in 18 normal breast tissues, five ductal carcinoma in situ (DCIS). 24 primary breast tumor tissue, and five distant metastases. The mRNA transcript level of each gene was normalized to the amount of beta-actin present in the samples. We observed differential gene expression of the selected TGF-beta family members as well as OPN in breast cancer progression. The average gene expression of the putative tumor suppressor, inhibin alpha, did not significantly change in any of the tumor tissues examined compared to normal breast tissue. The mRNA level of BMP-2, a protein with anti-proliferative effects in breast cancer cell lines and involved in bone formation, significantly decreased in non-invasive, invasive, and liver metastatic breast tumor tissue compared to normal breast tissue. The gene expression of activin betaA, a protein involved in cell proliferation and osteoclast induction, increased in invasive and bone metastatic tumor tissue compared to normal breast tissue. The mRNA level of OPN, a bone matrix protein associated with enhanced malignancy, increased in non-invasive, invasive, and liver and bone metastatic breast tumor tissue compared to normal breast tissue. In contrast, the average gene expressions of the TNF family members, RANKL and OPG, proteins involved in the regulation of osteoclastogenesis, were only slightly if at all changed in the different stage breast tumor tissues. These results suggest that differential gene expression of bone-related proteins, especially OPN, activin betaA, and BMP-2, by primary breast tumor tissues may play a significant role in the invasiveness and metastatic potential of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206515     DOI: 10.1023/a:1016339120506

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

2.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells.

Authors:  Chuan Wang; Fen Hu; Shaocong Guo; Dong Mi; Wenwen Shen; Jie Zhang; Yuhuan Qiao; Tianhui Zhu; Shuang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-07       Impact factor: 4.553

4.  RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.

Authors:  J T Ney; T Fehm; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-05       Impact factor: 2.915

5.  Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?

Authors:  Jasmin Otten; Carsten Bokemeyer; Walter Fiedler
Journal:  J Oncol       Date:  2010-05-13       Impact factor: 4.375

6.  Osteopontin is a marker for cancer aggressiveness and patient survival.

Authors:  G F Weber; G S Lett; N C Haubein
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

7.  Species-specific cis-regulatory elements in the 3'-untranslated region direct alternative polyadenylation of bone morphogenetic protein 2 mRNA.

Authors:  Donglin Liu; David T Fritz; Melissa B Rogers; Aaron J Shatkin
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

8.  Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.

Authors:  S S Cross; R F Harrison; S P Balasubramanian; J M Lippitt; C A Evans; M W R Reed; I Holen
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

9.  Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway.

Authors:  Guo-Xin Zhang; Zhi-Quan Zhao; Hong-Di Wang; Bo Hao
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

10.  FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis.

Authors:  D J Mulder; I Pacheco; D J Hurlbut; N Mak; G T Furuta; R J MacLeod; C J Justinich
Journal:  Gut       Date:  2008-10-31       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.